Learn how AbbVie could help you save on SKYRIZI.
Call 1.866.SKYRIZI or click tap to learn more ▸

Skip to Main content
  • Important Safety Information
  • Full Prescribing Information & Patient Information
    • Full Prescribing Information (English)
    • Medication Guide
  • Healthcare Professionals Site
Logo For Adults with Moderate to Severe Plaque Psoriasis
  • Cost & Savings
  • Sign in or Register
  • Logout
  • test
  • SKYRIZI
  • Change condition
    • Moderate to Severe Plaque Psoriasis
    • Active Psoriatic Arthritis
    • Moderate to Severe Crohn's Disease
  • SKYRIZI RESULTS
    • See SKYRIZI Results
    • Before & After SKYRIZI
    • SKYRIZI vs HUMIRA (adalimumab)
    • Real Patient Stories
    • SKYRIZI Patient Community
  • ABOUT SKYRIZI
    • What Is SKYRIZI
    • How SKYRIZI Works
    • SKYRIZI Dosing
    • SKYRIZI Side Effects
  • Plaque Psoriasis
    • What Is Plaque Psoriasis?
    • Psoriasis Symptoms
    • What Causes Plaque Psoriasis?
    • Inflammation and Psoriasis
  • Asking About SKYRIZI
    • Partner With Your Doctor
    • Find A Dermatologist
    • Prepare For Your Appointment
  • Starting SKYRIZI
    • About Skyrizi Complete
    • Ways to Save
    • Your Nurse Ambassador
    • Injection Support
    • Resources to Stay on Track
  • MANAGING YOUR TREATMENT
    • Preparing for Treatment
    • Understanding Insurance
    • Living With Your Condition
    • Share Your Story
  • Sign In or Register
  • Cost & Savings

USE

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

  • Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
    • - fainting, dizziness, feeling lightheaded
      (low blood pressure)
    • - swelling of your face, eyelids, lips, mouth,
      tongue, or throat
    • - trouble breathing or throat tightness
    • - chest tightness
    • - skin rash, hives
    • - itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

  • Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
    • - fever, sweats, or chills
    • - cough
    • - shortness of breath
    • - blood in your mucus (phlegm)
    • - muscle aches
    • - warm, red, or painful skin
      or sores on your body different from your psoriasis
    • - weight loss
    • - diarrhea or stomach pain
    • - burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?"
  • have an infection that does not go away or that keeps coming back.
  • have TB or have been in close contact with someone with TB.
  • have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
  • are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
  • become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk with your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

Liver problems in Crohn's disease: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and up to 12 weeks of treatment and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

USES

SKYRIZI is a prescription medicine used to treat adults with:

  • moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
  • active psoriatic arthritis (PsA).
  • moderate to severe Crohn's disease.

US-SKZ-220579

Please see the Full Prescribing Information, including the Medication Guide, for SKYRIZI.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.

Legal Notices/Privacy Policy. Copyright 2022, AbbVie Inc., North Chicago, Illinois, U.S.A. If you have any questions about AbbVie’s SKYRIZI.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.

SKYRIZI (risankizumab-rzaa)
  • Moderate to Severe Plaque Psoriasis Home
  • See SKYRIZI Results
  • What Is SKYRIZI?
  • What Is Plaque Psoriasis?
  • Find a Dermatologist
  • Resource Center
  • About Skyrizi Complete
  • Cost & Savings
  • Sitemap
Important Safety Information for Patients
  • Important Safety Information
  • Medication Guide
  • Full Prescribing Information
Information from AbbVie
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Advertising Choices
  • Healthcare Professionals Site
  • Cookies Settings

Leaving AbbVie Web Site

You are leaving the SKYRIZI site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-SKZ-220373

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are about to enter a site that is for US healthcare professionals only. By continuing, you certify that you are a healthcare professional and that you wish to proceed to the healthcare professionals section of this site. Products or treatments described on this site are available in the US but may not be available in all other countries.

Iam a licensed healthcare professional and wish to proceed to the healthcare professionals section of this site.

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI.com or AbbVie.

Do you wish to leave this site?

Yes
No

US-SKZ-220373

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

Important Updates to the Medication Guide for
SKYRIZI® (risankizumab-rzaa) injection, for subcutaneous use

On January 21, 2022, the SKYRIZI (risankizumab-rzaa) Prescribing Information and Medication Guide were updated to include new information about serious allergic reactions. 

The following describes the recent changes to the SKYRIZI Medication Guide. Please refer to the full Prescribing Information and Medication Guide for additional safety information.

The following serious side effects were added to the section “What is the most important information I should know about SKYRIZI?”

SKYRIZI may cause serious side effects, including: 

Serious allergic reactions. Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

  • fainting, dizziness, feeling lightheaded (low blood pressure)
  • swelling of your face, eyelids, lips, mouth, tongue, or throat
  • trouble breathing or throat tightness
  • chest tightness
  • skin rash, hives
  • itching

Who should not use SKYRIZI?

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the end of the Medication Guide for a complete list of ingredients in SKYRIZI here.

This is not a complete list of all the changes made to the Prescribing Information and Medication Guide for SKYRIZI. Please refer to the full Prescribing Information and Medication Guide for additional safety information.

INDICATIONS1

SKYRIZI is a prescription medicine used to treat adults: 

• with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). 

• with active psoriatic arthritis (PsA).

Important Safety Information1

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

• Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

− fainting, dizziness, feeling lightheaded (low blood pressure)

− swelling of your face, eyelids, lips, mouth, tongue, or throat

− trouble breathing or throat tightness

− chest tightness

− skin rash, hives

− itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

• Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:

− fever, sweats, or chills

− cough

− shortness of breath

− blood in your mucus (phlegm)

− muscle aches

− warm, red, or painful skin or sores on your body different from your psoriasis

− weight loss

− diarrhea or stomach pain

− burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

• have any of the conditions or symptoms listed in the section “What is the most important information I should know about SKYRIZI?”

• have an infection that does not go away or that keeps coming back.

• have TB or have been in close contact with someone with TB.

• have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.

• are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.

• are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See “What is the most important information I should know about SKYRIZI?”

The most common side effects of SKYRIZI include upper respiratory infections, feeling tired, fungal skin infections, headache, and injection site reactions.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.

Please see accompanying full Prescribing Information or visit www.rxabbvie.com/pdf/skyrizi_pi.pdf.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
©2022 AbbVie. All rights reserved. US-SKZD-220015 January 2022

US-SKZ-220001

Leaving AbbVie Web Site

You are leaving the SKYRIZI (risankizumab-rzaa) site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.

Conversely, the presence of this link does not imply the linked site's endorsement of SKYRIZI or AbbVie.

Do you wish to leave this site?

Yes
No

US-RISN-190090

USE

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your immune system to fight infections and may increase

IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your

USE

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your immune system to fight infections and may increase

IMPORTANT SAFETY INFORMATION

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions: Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:

• fainting, dizziness, feeling lightheaded (low blood pressure) • swelling of face, eyelids, lips, mouth, tongue, or throat • trouble breathing or throat tightness • chest tightness • skin rash, hives • itching

Infections: SKYRIZI may lower the ability of your

USE

SKYRIZI is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

  • Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
    • - fainting, dizziness, feeling lightheaded
      (low blood pressure)
    • - swelling of your face, eyelids, lips, mouth,
      tongue, or throat
    • - trouble breathing or throat tightness
    • - chest tightness
    • - skin rash, hives
    • - itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

  • Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
    • - fever, sweats, or chills
    • - cough
    • - shortness of breath
    • - blood in your mucus (phlegm)
    • - muscle aches
    • - warm, red, or painful skin
      or sores on your body different from your psoriasis
    • - weight loss
    • - diarrhea or stomach pain
    • - burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

  • have any of the conditions or symptoms listed in the section "What is the most important information I should know about SKYRIZI?"
  • have an infection that does not go away or that keeps coming back.
  • have TB or have been in close contact with someone with TB.
  • have recently received or are scheduled to receive an immunization (vaccine). Medicines that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
  • are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
  • become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk with your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

Liver problems in Crohn's disease: A person with Crohn's disease who received SKYRIZI through a vein in the arm developed changes in liver blood tests with a rash that led to hospitalization. Your healthcare provider will do blood tests to check your liver before, during, and up to 12 weeks of treatment and may stop treatment with SKYRIZI if you develop liver problems. Tell your healthcare provider right away if you notice any of the following symptoms: unexplained rash, nausea, vomiting, stomach (abdominal) pain, tiredness (fatigue), loss of appetite, yellowing of the skin and eyes (jaundice), and dark urine.

The most common side effects of SKYRIZI in people treated for Crohn’s disease include: upper respiratory infections, headache, joint pain, stomach (abdominal) pain, injection site reactions, low red blood cells (anemia), fever, back pain, and urinary tract infection.

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen, a 600 mg/10 mL vial for intravenous infusion, and a 180 mg/1.2 mL or 360 mg/2.4 mL single-dose prefilled cartridge with on-body injector.

USES

SKYRIZI is a prescription medicine used to treat adults with:

  • moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
  • active psoriatic arthritis (PsA).
  • moderate to severe Crohn's disease.

US-SKZ-220579